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The IVAN trial is a multi-centre factorial non-inferiority
randomised controlled trial of 610 participants to com-
pare treatments for neovascular Age-related Macular
Degeneration (two drugs, Lucentis and Avastin, and two
treatment regimens, treatment monthly and treatment
as-needed). Many of the trial outcomes are longitudinal
continuous outcomes measured at regular intervals over
the two-year study period.
The aim of the analyses was to obtain estimates of the
drug and treatment regimen effects at two-years. For
many of the outcomes, standard mixed-effects models
fitted the data well. However, for some secondary out-
comes, and in particular total lesion area, the distribu-
tions were highly skewed; 28% of 1536 measurements of
lesion area were zero indicating a lesion was not pre-
sent, which rendered standard regression modelling
unsuitable.
One approach taken to analyse this outcome was to
dichotomise the variable into lesion present and lesion
absent, and fit a logistic regression model with repeated
measures. This analysis identified a statistically signifi-
cant difference between the proportions of patients with
no lesion present at two-years on the different treatment
regimens. However the analysis did not make full use of
the data available and information about the size of the
lesion was not evaluated.
An alternative approach that we have investigated is to
use two-part modelling whereby the dichotomised data
is analysed using logistic regression, and the non-zero
values then analysed using mixed-effects models. We
will present the results of this analysis and describe the
methodological challenges faced when implementing it
in the context of the IVAN trial.
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